Tofacitinib in the treatment of primary Sjögren’s syndrome-associated interstitial lung disease: study protocol for a prospective, randomized, controlled and open-label trial

INTRODUCTION: Tofacitinib, a selective inhibitor of JAK1 and/or JAK3, is considered to alleviate the pulmonary condition of primary Sjögren’s syndrome (pSS)-associated interstitial lung disease (ILD) through its anti-inflammatory and antifibrotic effects. METHODS AND ANALYSIS: This is a single-cente...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Ronglin, Pu, Jincheng, Wang, Yanqing, Wu, Zhenzhen, Liang, Yuanyuan, Song, Jiamin, Pan, Shengnan, Han, Fang, Yang, Lufei, Xu, Xianghuai, Tang, Jianping, Wang, Xuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676577/
https://www.ncbi.nlm.nih.gov/pubmed/38007449
http://dx.doi.org/10.1186/s12890-023-02774-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676577/
https://www.ncbi.nlm.nih.gov/pubmed/38007449
http://dx.doi.org/10.1186/s12890-023-02774-0

Ejemplares similares